Bayer, Elanco could lock up animal health merger next week: report
When rumors emerged nearly a year ago that Bayer might be planning to exit the animal-health business, Eli Lilly spinoff Elanco was not at the top of any market-watcher’s list of potential buyers—especially not after it became clear that several private equity players were interested in the asset. Turns out Elanco was interested, and the… Read More »
